Publication:
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study

Simple item page
cris.virtualsource.author-orcidbed2f732-ad8f-46da-b23e-e9db6529c5f6
cris.virtualsource.author-orcidd15fbd74-75d8-4d5c-af34-c5ddef96dc39
cris.virtualsource.author-orcid3ada9c2f-a4dd-4760-84b1-c48e64972bc5
cris.virtualsource.author-orcidf34c7371-748b-4478-8d2e-40dddd291954
datacite.rightsopen.access
dc.contributor.authorMueller, F
dc.contributor.authorBüchel, Barbara
dc.contributor.authorKöberle, D
dc.contributor.authorSchürch, Stefan
dc.contributor.authorPfister, B
dc.contributor.authorKrähenbühl, St
dc.contributor.authorFröhlich, Tanja
dc.contributor.authorLargiadèr, Carlo Rodolfo
dc.contributor.authorJoerger, M
dc.date.accessioned2024-10-11T13:37:27Z
dc.date.available2024-10-11T13:37:27Z
dc.date.issued2013
dc.description.abstractThis study was initiated to assess the quantitative impact of patient anthropometrics and dihydropyrimidine dehydrogenase (DPYD) mutations on the pharmacokinetics (PK) of 5-fluorouracil (5FU) and to explore limited sampling strategies of 5FU.
dc.description.numberOfPages10
dc.description.sponsorshipUniversitätsinstitut für Klinische Chemie (UKC)
dc.description.sponsorshipDepartement für Chemie und Biochemie (DCB)
dc.identifier.doi10.48350/14661
dc.identifier.isi000314044200010
dc.identifier.pmid23139054
dc.identifier.publisherDOI10.1007/s00280-012-2018-4
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/84720
dc.language.isoen
dc.publisherSpringer
dc.publisher.placeBerlin
dc.relation.ispartofCancer chemotherapy and pharmacology
dc.relation.issn0344-5704
dc.relation.organizationDCD5A442BA49E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442C14DE17DE0405C82790C4DE2
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.subject.ddc500 - Science::570 - Life sciences; biology
dc.subject.ddc500 - Science::540 - Chemistry
dc.titleGender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage70
oaire.citation.issue2
oaire.citation.startPage361
oaire.citation.volume71
oairecerif.author.affiliationUniversitätsinstitut für Klinische Chemie (UKC)
oairecerif.author.affiliationDepartement für Chemie und Biochemie (DCB)
oairecerif.author.affiliationUniversitätsinstitut für Klinische Chemie (UKC)
oairecerif.author.affiliationUniversitätsinstitut für Klinische Chemie (UKC)
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2022-07-07 12:57:59
unibe.description.ispublishedpub
unibe.eprints.legacyId14661
unibe.journal.abbrevTitleCANCER CHEMOTH PHARM
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
Mueller2013_Article_Gender-specificEliminationOfCo.pdf
Size:
380.8 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
publisher
Content:
published
Download

Collections

Publications